Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy
This study has been completed.
Study NCT00004450 Information provided by FDA Office of Orphan Products Development
First Received: October 18, 1999 Last Updated: June 23, 2005
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Adrenoleukodystrophy
Additional conditions recognized in this trial
Addison Disease
More general conditions related to this trial
Adrenal Gland Diseases
Adrenal Insufficiency
Autoimmune Diseases
Brain Diseases
Brain Diseases, Metabolic
Brain Diseases, Metabolic, Inborn
Central Nervous System Diseases
Demyelinating Diseases
Endocrine System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Hereditary Central Nervous System Demyelinating Diseases
Heredodegenerative Disorders, Nervous System
Immune System Diseases
Mental Retardation
Mental Retardation, X-Linked
Metabolic Diseases
Metabolism, Inborn Errors
Nervous System Diseases
Neurobehavioral Manifestations
Neurologic Manifestations
Peroxisomal Disorders
Interventions listed in this trial
glyceryl trierucate
glyceryl trioleate
interferon beta
thalidomide
Additional drug interventions recognized in this trial
Interferon-beta
Interferons
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
FDA Office of Orphan Products Development
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Back to top of Main Content
